Friends of Cancer Research is our country's leading voice in advocating for policies and solutions that will get treatments to patients in the safest and quickest way posible.
Since President Obama signed the Breakthrough Therapy designation into law as part of the Food and Drug Administration Safety and Innovation Act, there have already been nine designations announced.
Senator Michael Bennet gave opening remarks at our July briefing on Breakthrough Therapy
Friends of Cancer Research's 2012 Annual Report is now available for download.
Friends Honors Governor Martin O'Malley, Governor Bob McDonnell, and philanthropist Sherry Lansing
National Institutes of Health Director Francis Collins talks about personalized medicine, sequestration, and the future of biomedical research in America on our new forum, Engaging Innovation.
Daclatasvir/asunaprevir combination - (Bristol-Meyers)
for the treatment of genotype 1b hepatitis C
Promacta/Revolade (eltrombopag) - (GlaxoSmithKline)
for the treatment of severe aplastic anemia
VX-661/Kalydeco - (Vertex)
in combination for the treatment of cystic fibrosis in patients with two copies of the F508del mutation
Dr. William W. Chin, Executive Vice President of Scientific and Regulatory Affairs for PhRMA, talks about his experience with public-private partnerships.
"There isn't a day where I'm not overwhelmed by how many people are dealing with this disease, and that's what drives all of our work at Friends of Cancer Research."
FRIENDS OF CANCER RESEARCH1800 M Street NW Suite 1050 | Washington, DC 20036202.944.6700